Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis

Psychiatry Res. 2011 Jan 30;185(1-2):286-9. doi: 10.1016/j.psychres.2010.06.006. Epub 2010 Jun 29.

Abstract

Genetic factors play an important role in the understanding of clinical response to antipsychotic treatments. We aimed to assess the effect of the catechol-O-methyltransferase (COMT) genotype in the short-term (6 weeks) clinical response of 161 first-episode psychosis patients. COMT genotype was not related to clinical response at 6 weeks. Val homozygote patients showed higher negative symptoms than Met homozygote patients. The COMT Val158 genotype seems to be related to the severity of negative symptoms rather than to clinical response.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Analysis of Variance
  • Antipsychotic Agents / therapeutic use*
  • Catechol O-Methyltransferase / genetics*
  • DNA Mutational Analysis
  • Double-Blind Method
  • Female
  • Gene Frequency
  • Genotype
  • Humans
  • Longitudinal Studies
  • Male
  • Methionine / genetics*
  • Middle Aged
  • Pharmacogenetics
  • Polymorphism, Genetic / genetics*
  • Psychiatric Status Rating Scales
  • Psychotic Disorders* / drug therapy
  • Psychotic Disorders* / genetics
  • Psychotic Disorders* / physiopathology
  • Regression Analysis
  • Treatment Outcome
  • Valine / genetics*
  • Young Adult

Substances

  • Antipsychotic Agents
  • Methionine
  • Catechol O-Methyltransferase
  • Valine